journal article·2026-05Open access

Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

Kalpana Ravi, Shannon Trottier, Obed B. Amissah, Grace C. Russell, Daniel Rho, Gloria B. Kim, Mehdi Nikkhah

Abstract

Immunotherapies such as chimeric antigen receptor (CAR) T cells have shown promising outcomes in hematological cancer but face challenges in targeting solid tumors like glioblastoma (GBM). Advancing this therapy for GBM has been hindered by the lack of preclinical tools that accurately model the complex interplay between CAR T cells and tumor cells within the tumor microenvironment (TME) — interactions critical for optimizing CAR constructs and improving efficacy. Physiologically relevant models that closely mimic the solid TME are therefore highly sought after in developing CAR T therapies. Here, we report a microengineered glioblastoma-on-a-chip (GOC) model with a functional vascular network to investigate the efficacy and selectivity of IL-13 mutein CAR T cells (TV-13) against U87 GBM tumor cells expressing high interleukin-13 receptor alpha-2 (IL13Rα2), compared with the ubiquitously expressed IL13Rα1. This biomimetic platform recapitulates the GBM TME and enables dynamic evaluation of CAR T cell responses under locoregional administration, paralleling clinical approaches. Using the organotypic GOC model, we evaluated CAR T cell-mediated inhibition of GBM invasion, monitored real-time dynamic CAR T-U87 interactions, and quantified the release of cytotoxic, proinflammatory, and stimulation-associated cytokines as measures of T cell effector function. CAR T cells induced a density-dependent reduction in U87 migration, accompanied by robust cytokine release, while TV-13 maintained specificity towards IL13Rα2 tumor antigen over IL13Rα1. Additionally, we further demonstrated the efficacy of CAR T cells against patient-derived GBM cells within the GOC model. Collectively, these findings highlight the GOC platform as a powerful preclinical screening tool for cancer immunotherapy optimization. • Effective CAR T therapies for solid tumors like GBM remain challenging. • Glioblastoma-on-chip was engineered to recapitulate 3D tumor microenvironment. • Enables locoregional CAR T administration paralleling clinical setting. • Human-relevant model for CAR T cytotoxicity, efficacy, and cytokine release. • Enables functional characterization of IL-13 and TV-13 CAR T cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: CAR-T cell therapy research · Monoclonal and Polyclonal Antibodies Research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (95)

Show source-provided references
1. Kanderi · 2024
2. Gene therapy in glioblastoma multiforme: can it be a role changer?10.1016/j.heliyon.2024.e27087 ↗
3. Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies
4. Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme10.1038/s41419-024-06904-2 ↗
5. Glioblastoma vasculature: from its critical role in tumor survival to relevant in vitro modelling10.3389/fddev.2022.823412 ↗
6. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers10.1016/j.jcyt.2024.03.484 ↗
7. Epidermal growth factor receptor and variant III targeted immunotherapy10.1093/neuonc/nou236 ↗
8. EGFRvIII‐targeted vaccination therapy of malignant glioma10.1111/j.1750-3639.2009.00318.x ↗
9. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma10.1016/j.neo.2022.100801 ↗
10. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours10.1038/s41571-022-00704-3 ↗
11. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma10.1056/NEJMoa1817226 ↗
12. Chimeric antigen receptor T cells in refractory B-cell lymphomas10.1056/NEJMoa1708566 ↗
13. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma10.1073/pnas.1819745116 ↗
14. CAR-T cell therapy: a game-changer in cancer treatment and beyond10.1007/s12094-023-03368-2 ↗
15. Navigating CAR-T cells through the solid-tumour microenvironment10.1038/s41573-021-00189-2 ↗
16. Advances in CAR-T therapy for central nervous system tumors10.1186/s40364-024-00679-6 ↗
17. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors10.3390/cancers14235983 ↗
18. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R⍺2 tumor-restricted biomarker10.1093/neuonc/nos211 ↗
19. Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis10.1371/journal.pone.0077769 ↗
20. Targeting tumor-associated antigen: a promising CAR-T therapeutic strategy for glioblastoma treatment
21. Identification of a novel role of IL13Rα2 in human glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway10.1186/s12967-018-1746-6 ↗
22. IL13R⍺2 is overexpressed in malignant gliomas and related to clinical outcome of patients
23. High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma
24. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy10.1007/s00262-023-03423-5 ↗
25. Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy10.1126/scitranslmed.abo6135 ↗
26. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy10.1073/pnas.2112006119 ↗
27. Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma10.1016/j.ymthe.2017.10.002 ↗
28. Locoregional delivery of CAR-T cells in the clinic10.1016/j.phrs.2022.106329 ↗
29. Locoregional delivery of IL13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial10.1038/s41591-024-02875-1 ↗
30. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL13Rα2 are effective against heterogeneous glioblastoma
31. Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma10.1158/1078-0432.CCR-15-0428 ↗
32. Preclinical evaluation of CAR T cell function: in vitro and in vivo models10.3390/ijms23063154 ↗
33. Preclinical mouse cancer models: a maze of opportunities and challenges10.1016/j.cell.2015.08.068 ↗
34. Analysis and augmentation of the immunologic bystander effects of CAR T cell therapy in a syngeneic mouse cancer model10.1016/j.omto.2020.07.005 ↗
35. Preclinical models in chimeric antigen receptor-engineered T-Cell therapy10.1089/hum.2017.243 ↗
36. Applying a clinical lens to animal models of CAR-T cell therapies10.1016/j.omtm.2022.08.008 ↗
37. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models10.1136/jitc-2021-003486 ↗
38. 3D tumor models and their use for the testing of immunotherapies10.3389/fimmu.2020.603640 ↗
39. Applications of microfluidics and organ-on-a-chip in cancer research10.3390/bios12070459 ↗
40. Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis10.1016/j.biomaterials.2017.04.017 ↗
41. The role of desmoplasia and stromal fibroblasts on anti-cancer drug resistance in a microengineered tumor model10.1007/s12195-018-0544-9 ↗
42. The role of tumor-stroma interactions on desmoplasia and tumorigenicity within a microengineered 3D platform10.1016/j.biomaterials.2020.119975 ↗
43. Advancing tumor-on-a-chip technologies: a 3D-printed, PDMS-free biochip for breast cancer studies10.1088/1758-5090/ae2719 ↗
44. Modelling cancer in microfluidic human organs-on-chips10.1038/s41568-018-0104-6 ↗
45. Microengineered 3D tumor models for anti-cancer drug discovery in female-related cancers
46. Organ-on-a-chip: key industry insights, challenges, and opportunities from 100+ NSF I-Corps interviews10.1039/D5LC00426H ↗
47. The origins and the future of microfluidics10.1038/nature05058 ↗
48. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion10.1126/sciadv.abc2331 ↗
49. Human organs-on-chips for disease modelling, drug development and personalized medicine10.1038/s41576-022-00466-9 ↗
50. Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor–stroma microfluidic model10.1039/c7ib00180k ↗
51. Engineered 3D ex vivo models to recapitulate the complex stromal and immune interactions within the tumor microenvironment
52. A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells10.1158/0008-5472.CAN-18-2293 ↗
53. Tumor microenvironment on‐a‐chip and single‐cell analysis reveal synergistic stromal–immune crosstalk on breast cancer progression
54. Fabrication method of a high-density Co-Culture tumor–stroma platform to study cancer progression10.1007/978-1-0716-1174-6_16 ↗
55. Microfluidic tumor–vascular model to study breast cancer cell invasion and intravasation10.1002/adhm.201701257 ↗
56. Investigating the interactions of glioma stem cells in the perivascular niche at single‐cell resolution using a microfluidic tumor microenvironment model10.1002/advs.202201436 ↗
57. A three-dimensional (3D) organotypic microfluidic model for glioma stem cells–vascular interactions10.1016/j.biomaterials.2018.07.048 ↗
58. Advancing targeted drug delivery in glioblastoma multiforme through biomimetic nanomedicine using 3D Tumor-On-a-Chip model
59. Evaluating CAR‐T cell therapy in a hypoxic 3D tumor model
60. New strategy for promoting vascularization in tumor spheroids in a microfluidic assay10.1002/adhm.202201784 ↗
61. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells10.1016/j.stem.2024.04.018 ↗
62. Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics
63. A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors
64. Improved expansion and in vivo function of patient T cells by a serum-free medium10.1016/j.omtm.2017.11.001 ↗
65. CAR talk: how cancer-specific CAR T cells can instruct how to build CAR T cells to cure HIV10.3389/fimmu.2019.02310 ↗
66. SPICE: exploration and analysis of post‐cytometric complex multivariate datasets10.1002/cyto.a.21015 ↗
67. Perforin and granzymes: function, dysfunction and human pathology10.1038/nri3839 ↗
68. Imaging and monitoring of granzyme B in the immune response10.1002/wnan.1928 ↗
69. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response10.1186/s40425-017-0293-7 ↗
70. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover10.1084/jem.20070784 ↗
71. Improving CAR T cell therapy by optimizing critical quality attributes
72. 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes10.1016/j.biomaterials.2018.07.014 ↗
73. Characterization and comparison of human glioblastoma models10.1186/s12885-022-09910-9 ↗
74. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U8710.1016/j.canlet.2008.02.010 ↗
75. Evolution of experimental models in the study of glioblastoma: toward finding efficient treatments10.3389/fonc.2020.614295 ↗
76. Car T cells in solid tumors: overcoming obstacles10.3390/ijms25084170 ↗
77. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes10.1016/j.medj.2022.05.001 ↗
78. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
79. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn10.1038/s41571-023-00832-4 ↗
80. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment10.1186/s40164-023-00373-7 ↗
81. A roadmap of CAR-T-Cell therapy in glioblastoma: challenges and future perspectives10.3390/cells13090726 ↗
82. Efficacy, safety, and challenges of CAR T-Cells in the treatment of solid tumors10.3390/cancers14235983 ↗
83. Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells10.1039/D4LC01089B ↗
84. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies10.1186/s12987-022-00342-y ↗
85. The vascular microenvironment in glioblastoma: a comprehensive review10.3390/biomedicines10061285 ↗
86. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity10.1073/pnas.1716266115 ↗
87. Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications10.3389/fimmu.2022.947648 ↗
88. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity10.1172/jci.insight.99048 ↗
89. Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy10.1016/j.biopha.2024.117753 ↗
90. Polyfunctional responses by human T cells result from sequential release of cytokines10.1073/pnas.1117194109 ↗
91. Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms10.1016/j.trecan.2022.12.003 ↗
92. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition10.1038/s41419-024-06461-8 ↗
93. Control of CAR-T cell activity in space and time: the next level of anti-tumor action10.1038/s41392-023-01424-5 ↗
94. Engineered tumor-immune microenvironment on A chip to study T cell-macrophage interaction in breast cancer progression10.1002/adhm.202303658 ↗
95. Engineering T cells to survive and thrive in the hostile tumor microenvironment10.1016/j.cobme.2021.100360 ↗